Joseph is the Vice President of Scientific Affairs on the Biotherapeutics group at Deerfield and joined the Firm in 2017. Prior to Deerfield, Joseph was the Vice President of Clinical Development at Infinity Pharmaceuticals. Before Infinity Pharmaceuticals, Joseph worked as a Medical Director in the oncology unit of Sanofi. He received his MD at the University of California, San Francisco, and completed his clinical training at the Massachusetts General Hospital and Dana Farber Cancer Institute. He earned his PhD in Molecular Biology from Harvard University and was a Lecturer in the Department of Biological Chemistry and Molecular Pharmacology at Harvard Medical School.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Nuvalent
1 followers
Nuvalent is creating precisely targeted therapies for patients with cancer designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in structure-based design, Nuvalent develops innovative small molecules with exquisite target selectivity to overcome resistance, minimize adverse events, and drive more durable responses.